Thymosin Alpha 1 (Ta1)

Synthetic Thymic Hormone | Immune System Modulator

Weight: 3,108 Da
Half-life: ~2 hours
Chain: 28 amino acids
4 studies
2025 latest
2 recent
Well Studied
Dose 1.6mg per injection (standard dose across all protocols)
Frequency 2x weekly (e.g., Monday and Thursday) for standard immune support
Cycle 6 months continuous for therapeutic protocols
Storage Use immediately after reconstitution or refrigerate up to 2 hours
Accumulation Plotter

Community Research

Join others researching Thymosin Alpha 1 — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings
Discussion Questions & experiences
Submit Your Findings Contribute your research data

Thymosin Alpha 1 is a synthetic 28-amino acid peptide identical to naturally occurring thymic hormone, studied in 11,000+ patients across 30+ clinical trials with less than 1% serious adverse events. Approved in 35+ countries for immune modulation.

Mechanism of Action

Activates TLR pathways, enhances T-cell maturation, stimulates NK cells, and modulates dendritic cell function via systemic circulation. Injectable route achieves 90-95% bioavailability with 2-hour peak time.

01 Primary FDA-studied route with extensive clinical validation
02 Maximum immune modulation through systemic circulation
03 Established dosing from 35+ countries of clinical use
04 Exceptional safety profile (<1% serious adverse events)
05 Reduces pro-inflammatory cytokines 40-60%
06 Approved in 35+ countries

Molecular Data

Molecular Weight
3,108 Da
Chain Length
28 amino acids
Type
Acetylated polypeptide
Amino Acid Sequence
One-letter: ?SDAAVDTSSEITTKDLKEKKEVVEEAEN
H₂N
H
? 1
O ‖ C
N
S 2
O ‖ C
N
D 3
O ‖ C
N
A 4
O ‖ C
N
A 5
O ‖ C
N
V 6
O ‖ C
N
D 7
O ‖ C
N
T 8
O ‖ C
N
S 9
O ‖ C
N
S 10
O ‖ C
N
E 11
O ‖ C
N
I 12
O ‖ C
N
T 13
O ‖ C
N
T 14
O ‖ C
N
K 15
O ‖ C
N
D 16
O ‖ C
N
L 17
O ‖ C
N
K 18
O ‖ C
N
E 19
O ‖ C
N
K 20
O ‖ C
N
K 21
O ‖ C
N
E 22
O ‖ C
N
V 23
O ‖ C
N
V 24
O ‖ C
N
E 25
O ‖ C
N
E 26
O ‖ C
N
A 27
O ‖ C
N
E 28
O ‖ C
N
N 29
COOH
Ac
1

Ac

Position 1

Ser
2

Serine

Position 2

Asp
3

Aspartic Acid

Position 3

Ala
4

Alanine

Position 4

Ala
5

Alanine

Position 5

Val
6

Valine

Position 6

Asp
7

Aspartic Acid

Position 7

Thr
8

Threonine

Position 8

Ser
9

Serine

Position 9

Ser
10

Serine

Position 10

Glu
11

Glutamic Acid

Position 11

Ile
12

Isoleucine

Position 12

Thr
13

Threonine

Position 13

Thr
14

Threonine

Position 14

Lys
15

Lysine

Position 15

Asp
16

Aspartic Acid

Position 16

Leu
17

Leucine

Position 17

Lys
18

Lysine

Position 18

Glu
19

Glutamic Acid

Position 19

Lys
20

Lysine

Position 20

Lys
21

Lysine

Position 21

Glu
22

Glutamic Acid

Position 22

Val
23

Valine

Position 23

Val
24

Valine

Position 24

Glu
25

Glutamic Acid

Position 25

Glu
26

Glutamic Acid

Position 26

Ala
27

Alanine

Position 27

Glu
28

Glutamic Acid

Position 28

Asn
29

Asparagine

Position 29

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified
Peak 0.0 mcg
Trough 0.0 mcg
SS Peak 0.0 mcg
SS Trough 0.0 mcg

Research Indications

Immunity
Primary Immunodeficiencies most effective

FDA orphan designation for DiGeorge syndrome; restores T-cell function.

Vaccine Enhancement most effective

Improved antibody responses in elderly and hemodialysis patients (H1N1, COVID-19).

HIV/AIDS Support effective

Restores CD4+ counts and reduces opportunistic infections.

Inflammation
Cytokine Reduction effective

Reduces pro-inflammatory cytokines TNF-α, IL-1β, IL-6 by 40-60%.

Hepatitis B/C Support effective

Enhanced antiviral efficacy when combined with interferon.

Autoimmune Conditions moderate

Helps manage inflammatory autoimmune conditions.

Recovery
Post-Surgical Immune Restoration moderate

Restores immune function after surgical stress.

Exercise-Induced Immunosuppression moderate

Manages immune suppression from intense training.

Anti-Aging
Thymic Regeneration Support moderate

Supports thymus gland function with aging.

Immune Senescence Delay moderate

Delays age-related immune decline in elderly populations.

Dosing Protocols

Subcutaneous injection is the primary route with 90-95% bioavailability. Standard dosing is 1.6mg twice weekly.

GoalDoseFrequencyRoute
Standard immune support1.6mg2x weeklySubQ
Acute conditions (sepsis)1.6mg2x daily for 5 days, then dailySubQ/IM
Cancer/hepatitis support1.6mg2x weeklySubQ
Maintenance/prevention1.6mg2x weeklySubQ

Reconstitution Instructions

Materials Needed:
  • Thymosin Alpha 1 lyophilized powder
  • Sterile water (1.0mL)
  • Insulin syringes
  • Alcohol swabs
  1. 1 Clean work surface thoroughly
  2. 2 Add 1.0mL sterile water slowly to lyophilized powder
  3. 3 Inject water down vial side (avoid direct powder contact)
  4. 4 Gently swirl until fully dissolved (never shake)
  5. 5 Final concentration: 1.6mg/mL
  6. 6 Use immediately or refrigerate up to 2 hours

Interactions

!
Immunosuppressive Agents
Fatal graft rejection risk in transplant patients - contraindicated.
avoid
~
Corticosteroids
Pharmacodynamic antagonism possible.
monitor
++
Interferon-α
Enhanced antiviral efficacy in hepatitis treatment.
synergistic
+
Vaccines
Enhances vaccine immunogenicity.
compatible
+
Chemotherapy
Protective against bone marrow damage.
compatible

What to Expect

Week 1-2
Initial immune system activation
Week 2-6
Enhanced immune function, reduced infection risk
Week 6-12
Maximum immunomodulatory benefits
Week 12+
Sustained immune support with continued use

Side Effects & Safety

Common Side Effects

  • Mild injection site reactions (<10% incidence)
  • Generally well-tolerated with exceptional safety record

Stop Signs - Discontinue if:

  • Signs of graft rejection in transplant recipients
  • Persistent injection site reactions or infection signs
  • Unusual immune system hyperactivity
  • Severe allergic reactions (rare)

Contraindications

  • Organ transplant recipients (risk of graft rejection)
  • Pregnancy and breastfeeding

Quality Checklist

Good Signs

  • White, fluffy lyophilized powder filling vial bottom
  • Crystal clear solution after reconstitution (no particles/cloudiness)
  • Professional pharmaceutical labeling with batch numbers, expiration

Warning Signs

  • Minor powder compaction during shipping (acceptable if dissolves cleanly)

Bad Signs

  • Yellow, brown, or collapsed powder (heat/moisture degradation)
  • Persistent cloudiness or particles post-reconstitution
  • Non-professional sourcing or unclear labeling

References

  • Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells
    Liu Y, Pang Y, Hu Z, et al.
    Clinical Infectious Diseases (2020)

    Mortality significantly reduced in severe COVID-19: 11.11% with thymosin alpha 1 vs 30.00% untreated (P=0.044). Restored CD4+ and CD8+ T-cell numbers and reversed T-cell exhaustion markers PD-1 and Tim-3.

  • The Efficacy and Safety of Thymosin Alpha 1 for Sepsis (TESTS): Multicentre, Double-Blinded, Randomised, Placebo-Controlled, Phase 3 Trial
    Liu J, Li J, He L, et al.
    BMJ (2025)

    1,106 adults with sepsis across 22 centres. 28-day mortality: 23.4% thymosin alpha 1 vs 24.1% placebo (HR 0.99, P=0.93). No overall benefit, but prespecified subgroup analysis showed potential benefit in elderly and diabetic patients.

  • Thymosin Alpha 1: A Historical Overview
    Garaci E
    Annals of the New York Academy of Sciences (2007)

    Comprehensive overview of thymosin alpha 1 from discovery to clinical application. Evidence for combined treatments with interferon or IL-2 restoring immune responses depressed by tumor growth and/or cytostatic drugs.

  • Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials
    Johnson EK, et al.
    Expert Opinion on Drug Safety (2024)

    Narrative review of 11,000+ patients across 30+ clinical trials. Exceptional safety profile with <1% serious adverse events. Applications in COVID-19, autoimmune conditions, hepatitis, and cancer.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.